GeneDx Holdings Corp
WGS130.060USD
+2.060+1.61%
Close 12/31, 16:00（ET）Quotes delayed by 15 min
3.76BMarket Cap
1198.49P/E TTM
More Details of GeneDx Holdings Corp Company
GeneDx Holdings Corp. is a genomics company. The Company operates, through its subsidiary, GeneDx, LLC, which is focused on exome and genome tests that translate complex genomic data into clinical answers that unlock personalized health plans, accelerate drug discovery, and improve health system efficiencies. It operates through GeneDx segment, which primarily provides pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing and, to a lesser extent, data and information services. Exome sequencing test options include XomeDx, XomeDx Plus, and XomeDxXpress. GeneDx genome sequencing evaluates the protein-coding and non-coding regions of an individual’s nuclear genome. GeneDx genome sequencing test options include GenomeSeqDx and GenomeXpress. It offers a menu of targeted variant testing options to meet the needs of families and healthcare providers. Its subsidiary, Fabric Genomics, Inc., specializes in artificial intelligence-powered genomic interpretation.
GeneDx Holdings Corp Info
Ticker SymbolWGS
Company nameGeneDx Holdings Corp
IPO dateSep 04, 2020
CEOStueland (Katherine A)
Number of employees1000
Security typeOrdinary Share
Fiscal year-endSep 04
Address333 Ludlow Street
CitySTAMFORD
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code06902
Phone18887291206
Websitehttps://sema4.com/
Ticker SymbolWGS
IPO dateSep 04, 2020
CEOStueland (Katherine A)
Company Executives of GeneDx Holdings Corp
Name
Name/Position
Position
Shareholding
Change
Mr. Joshua Ruch
Mr. Joshua Ruch
Independent Director
Independent Director
223.99K
+6.12%
Dr. Emily M. Leproust, Ph.D.
Dr. Emily M. Leproust, Ph.D.
Independent Director
Independent Director
33.16K
+63.87%
Mr. Kevin Feeley
Mr. Kevin Feeley
Chief Financial Officer
Chief Financial Officer
4.46K
+8.26%
Mr. Keith A. Meister
Mr. Keith A. Meister
Independent Director
Independent Director
3.58K
-82.23%
Dr. Thomas Fuchs
Dr. Thomas Fuchs
Director
Director
--
--
Dr. Bryan Dechairo
Dr. Bryan Dechairo
Chief Operating Officer
Chief Operating Officer
--
--
Ms. Katherine A. Stueland
Ms. Katherine A. Stueland
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. Jason Michael Ryan, CPA
Mr. Jason Michael Ryan, CPA
Chairman of the Board
Chairman of the Board
--
--
Mr. Eli D. Casdin
Mr. Eli D. Casdin
Independent Director
Independent Director
--
--
Mr. Richard C. (Rick) Pfenniger, Jr.
Mr. Richard C. (Rick) Pfenniger, Jr.
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Joshua Ruch
Mr. Joshua Ruch
Independent Director
Independent Director
223.99K
+6.12%
Dr. Emily M. Leproust, Ph.D.
Dr. Emily M. Leproust, Ph.D.
Independent Director
Independent Director
33.16K
+63.87%
Mr. Kevin Feeley
Mr. Kevin Feeley
Chief Financial Officer
Chief Financial Officer
4.46K
+8.26%
Mr. Keith A. Meister
Mr. Keith A. Meister
Independent Director
Independent Director
3.58K
-82.23%
Dr. Thomas Fuchs
Dr. Thomas Fuchs
Director
Director
--
--
Dr. Bryan Dechairo
Dr. Bryan Dechairo
Chief Operating Officer
Chief Operating Officer
--
--
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
Patients with third party insurance
81.10M
78.98%
Institutional customers
18.38M
17.90%
Other
2.87M
2.79%
Self pay patients
339.00K
0.33%
Relevant data have not been disclosed by the company yet.
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Patients with third party insurance
81.10M
78.98%
Institutional customers
18.38M
17.90%
Other
2.87M
2.79%
Self pay patients
339.00K
0.33%
Shareholding Stats
Updated: Wed, Dec 3
Updated: Wed, Dec 3
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Corvex Management LP
10.58%
Casdin Capital, LLC
10.40%
Icahn School of Medicine at Mount Sinai
4.75%
OPKO Health Inc
4.74%
BlackRock Institutional Trust Company, N.A.
4.56%
Other
64.96%
Shareholders
Shareholders
Proportion
Corvex Management LP
10.58%
Casdin Capital, LLC
10.40%
Icahn School of Medicine at Mount Sinai
4.75%
OPKO Health Inc
4.74%
BlackRock Institutional Trust Company, N.A.
4.56%
Other
64.96%
Shareholder Types
Shareholders
Proportion
Investment Advisor/Hedge Fund
34.29%
Investment Advisor
31.31%
Hedge Fund
30.92%
Corporation
10.65%
Research Firm
6.78%
Individual Investor
1.68%
Pension Fund
0.76%
Bank and Trust
0.40%
Venture Capital
0.31%
Institutional Shareholding
Updated: 24 minutes ago
Updated: 24 minutes ago
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
482
30.37M
105.08%
-4.20M
2025Q3
446
32.52M
112.51%
-918.42K
2025Q2
397
34.23M
119.24%
+1.02M
2025Q1
398
32.79M
115.46%
-47.86K
2024Q4
341
29.17M
104.22%
+1.72M
2024Q3
289
26.18M
97.50%
+377.48K
2024Q2
262
24.98M
95.33%
+588.25K
2024Q1
260
22.13M
86.19%
+1.41M
2023Q4
271
20.57M
80.67%
-567.28K
2023Q3
283
21.68M
85.29%
-751.02K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Corvex Management LP
3.06M
10.65%
--
--
Aug 22, 2025
Casdin Capital, LLC
3.05M
10.6%
-461.51K
-13.16%
Aug 22, 2025
Icahn School of Medicine at Mount Sinai
1.37M
4.78%
-1.35M
-49.50%
Feb 21, 2025
OPKO Health Inc
1.37M
4.77%
-800.83K
-36.88%
Nov 20, 2024
BlackRock Institutional Trust Company, N.A.
1.28M
4.45%
+241.28K
+23.25%
Jun 30, 2025
William Blair Investment Management, LLC
1.63M
5.68%
+442.41K
+37.21%
Jun 30, 2025
The Vanguard Group, Inc.
1.18M
4.09%
+148.96K
+14.50%
Jun 30, 2025
Goldman Sachs & Company, Inc.
973.26K
3.39%
-59.05K
-5.72%
Jun 30, 2025
Oracle Investment Management, Inc.
922.45K
3.21%
-47.50K
-4.90%
Jun 30, 2025
Summit Partners Public Asset Management, LLC
767.26K
2.67%
-435.26K
-36.20%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Global X Genomics & Biotechnology ETF
3.84%
Franklin Genomic Advancements ETF
3.47%
Clough Hedged Equity ETF
2.89%
Clough Select Equity ETF
2.65%
State Street SPDR S&P Health Care Services ETF
2.27%
Harbor Health Care ETF
1.85%
Innovator IBD Breakout Opportunities ETF
1.52%
ARK Genomic Revolution ETF
1.29%
Main Thematic Innovation ETF
1.29%
Invesco Dorsey Wright Healthcare Momentum ETF
1.18%
View more
Global X Genomics & Biotechnology ETF
Proportion3.84%
Franklin Genomic Advancements ETF
Proportion3.47%
Clough Hedged Equity ETF
Proportion2.89%
Clough Select Equity ETF
Proportion2.65%
State Street SPDR S&P Health Care Services ETF
Proportion2.27%
Harbor Health Care ETF
Proportion1.85%
Innovator IBD Breakout Opportunities ETF
Proportion1.52%
ARK Genomic Revolution ETF
Proportion1.29%
Main Thematic Innovation ETF
Proportion1.29%
Invesco Dorsey Wright Healthcare Momentum ETF
Proportion1.18%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Apr 28, 2023
Merger
33→1
Apr 28, 2023
Merger
33→1
Apr 28, 2023
Merger
33→1
Apr 28, 2023
Merger
33→1
Date
Type
Ratio
Apr 28, 2023
Merger
33→1
Apr 28, 2023
Merger
33→1
Apr 28, 2023
Merger
33→1
Apr 28, 2023
Merger
33→1
FAQs
Who are the top five shareholders of GeneDx Holdings Corp?
The top five shareholders of GeneDx Holdings Corp are:
Corvex Management LP holds 3.06M shares, accounting for 10.65% of the total shares.
Casdin Capital, LLC holds 3.05M shares, accounting for 10.60% of the total shares.
Icahn School of Medicine at Mount Sinai holds 1.37M shares, accounting for 4.78% of the total shares.
OPKO Health Inc holds 1.37M shares, accounting for 4.77% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 1.28M shares, accounting for 4.45% of the total shares.
Corvex Management LP holds 3.06M shares, accounting for 10.65% of the total shares.
Casdin Capital, LLC holds 3.05M shares, accounting for 10.60% of the total shares.
Icahn School of Medicine at Mount Sinai holds 1.37M shares, accounting for 4.78% of the total shares.
OPKO Health Inc holds 1.37M shares, accounting for 4.77% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 1.28M shares, accounting for 4.45% of the total shares.
What are the top three shareholder types of GeneDx Holdings Corp?
The top three shareholder types of GeneDx Holdings Corp are:
Corvex Management LP
Casdin Capital, LLC
Icahn School of Medicine at Mount Sinai
Corvex Management LP
Casdin Capital, LLC
Icahn School of Medicine at Mount Sinai
How many institutions hold shares of GeneDx Holdings Corp (WGS)?
As of 2025Q4, 482 institutions hold shares of GeneDx Holdings Corp, with a combined market value of approximately 30.37M, accounting for 105.08% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -7.43%.
What is the biggest source of revenue for GeneDx Holdings Corp?
In FY2025Q2, the Patients with third party insurance business generated the highest revenue for GeneDx Holdings Corp, amounting to 81.10M and accounting for 78.98% of total revenue.
